Chronic Hepatitis

Top Story

DAAs produce cure rates in HCV/HIV co-infection similar to monoinfection

November 13, 2017

Using direct-acting antiviral therapies demonstrated similarly high rates of sustained virologic response for hepatitis C virus infection in patients with and without HIV infection as compared with rates for HCV mono-infected patients, according to findings published in Hepatology.

“Because of low [sustained virologic response] rates associated with interferon-based therapies, the accelerated progression of HCV related liver disease, and barriers to receiving treatment, the [FDA] identified those infected with HIV and HCV co-infection as being a specific population with unmet medical needs,” Cameron Sikavi, third-year resident from the department of medicine at Harbor-University of California at Los Angeles Medical Center, and colleagues wrote. “With the advent of [DAA] therapies, HCV treatment has resulted in higher cure rates with short treatment duration in comparison to pegylated-interferon and ribavirin based therapies, in addition to improved safety and tolerability profiles.”

Meeting News

More than 6 million treated for hepatitis globally

October 30, 2017
Since 2015, nearly 3 million people initiated treatment for hepatitis C, and in 2016 alone nearly 3 million initiated hepatitis B treatment, according to an announcement…

Mother-to-infant HCV transmission risk on the rise in Wisconsin

October 26, 2017
The proportion of pregnant women with hepatitis C virus infection who receive Medicaid in Wisconsin has risen dramatically, suggesting an increased risk for…
Meeting News

HCV clearance lowers liver cancer risk by 70% no matter drug of choice

October 24, 2017
WASHINGTON — Reaching sustained virologic response with direct-acting antivirals reduced the occurrence of hepatocellular carcinoma by 71%, but all…
More Headlines »
Advertisement
Advertisement